Specialty pharmaceutical company Mallinckrodt plc announced on Thursday that the Irish High Court has given the necessary ruling to enable its combination with Endo Inc (OTCQX:NDOI), advancing the companies' plan to merge in a stock and cash transaction that will create a global, scaled, diversified therapeutics company.

The court's ruling is the final substantive legal step required for the transaction and follows a vote by each company's shareholders last month to approve the merger. Mallinckrodt and Endo now expect to complete their combination in early August, pending the satisfaction of the remaining closing steps. Mallinckrodt's headquarters in Dublin, Ireland, will serve as the combined company's global headquarters.

As initially announced in March 2025, Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after the close of the transaction and to separate that business from the combined company at a later date. This separation will be subject to approval by the combined company's board of directors and other conditions.